Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance

Stock Track

11/12

CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.

The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.

Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.

In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.

The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1180427284"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180427284\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180427284?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180427284","market":"sg","top_or_hot":-1,"title":"Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance","media":"Stock Track","content":"<p>CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.</p>\n\n<p>The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.</p>\n\n<p>Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.</p>\n\n<p>In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.</p>\n\n<p>The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CorMedix Soars 9.47% Pre-Market on Stellar Q3 Results and Raised Guidance\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-11-12 20:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.</p>\n\n<p>The biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.</p>\n\n<p>Driving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.</p>\n\n<p>In light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.</p>\n\n<p>The market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRMD","symbol_name":"CorMedix Inc.","start_time":0,"source_url":"","article_id":"1180427284","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180427284","pubTimestamp":1762951706,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRMD":"CorMedix Inc."},"translate_title":"股票追踪|CorMedix盘前飙升9.47%，因第三季度业绩出色并上调指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRMD":1},"content_text":"CorMedix Inc. (CRMD) shares surged 9.47% in pre-market trading on Wednesday following the release of its impressive third-quarter 2025 financial results and an optimistic outlook for the full year.\nThe biopharma company reported a Q3 earnings per share (EPS) of $1.26, significantly outperforming the analysts' estimate of $0.65. Net income for the quarter reached $108.6 million, nearly doubling the expected $54.7 million. CorMedix also posted robust net revenue of $104.3 million for the quarter.\nDriving this strong performance was the higher-than-anticipated utilization of DefenCath by outpatient dialysis customers, which contributed $88.8 million to the net revenue. The company's integration of Melinta Therapeutics is reportedly ahead of schedule, capturing synergies of approximately $30 million.\nIn light of these positive results, CorMedix has raised its full-year 2025 guidance. The company now expects pro forma net revenue to be in the range of $390 to $410 million, up from its previous forecast. Additionally, CorMedix increased its 2025 pro forma adjusted EBITDA guidance to $220-$240 million.\nThe market's enthusiastic response to these results and the improved outlook underscores investor confidence in CorMedix's growth trajectory and operational efficiency. As the company continues to expand its product utilization and realize synergies from recent acquisitions, it appears well-positioned for sustained growth in the biopharmaceutical sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}